VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 37
- −1 vs. Q3 2024
- Portfolio value
- $1.46B
- −$451.8M (−23.7%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| TILInstil Bio, Inc. | COM NEW | 33,177 | $633.3K | <0.1% | 00.0% | Unchanged | History |
| CBIOCrescent Biopharma, Inc. | COM | 3,000,000 | $747.0K | 0.1% | +3,000,000 | New | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 208,333 | $1.29M | 0.1% | 00.0% | Unchanged | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,555,556 | $2.22M | 0.2% | 00.0% | Unchanged | History |
| CASIFCASI Pharmaceuticals, Inc. | ORD SHS | 987,259 | $2.79M | 0.2% | 00.0% | Unchanged | History |
| IPSCCentury Therapeutics, Inc. | COM | 3,957,186 | $4.00M | 0.3% | −1,432,073−26.6% | Reduced | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,023,166 | $5.06M | 0.3% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 1,266,457 | $5.22M | 0.4% | −2,156,199−63.0% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 3,225,180 | $5.58M | 0.4% | −5,774,820−64.2% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,077,090 | $5.97M | 0.4% | −2,332,968−68.4% | Reduced | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.63M | 0.5% | 00.0% | Unchanged | History |
| APLTApplied Therapeutics, Inc. | COM | 9,990,591 | $8.55M | 0.6% | +165,591+1.7% | Added | History |
| AQSTAquestive Therapeutics, Inc. | COM | 2,629,786 | $9.36M | 0.6% | −2,925,769−52.7% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,345,780 | $9.85M | 0.7% | 00.0% | Unchanged | History |
| MRSNMersana Therapeutics, Inc. | COM | 10,257,790 | $14.7M | 1.0% | −1,070,210−9.4% | Reduced | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 1,609,569 | $16.2M | 1.1% | 00.0% | Unchanged | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 2,952,371 | $16.4M | 1.1% | −1,447,629−32.9% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,379,965 | $16.8M | 1.2% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 765,723 | $20.6M | 1.4% | +765,723 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,457,348 | $22.0M | 1.5% | −1,001,297−29.0% | Reduced | History |
| MRUSMerus N.V. | COM | 592,411 | $24.9M | 1.7% | −315,552−34.8% | Reduced | History |
| ENGNenGene Therapeutics Inc. | COM | 5,046,414 | $33.6M | 2.3% | +1,480,573+41.5% | Added | History |
| ORICOric Pharmaceuticals, Inc. | COM | 4,394,527 | $35.5M | 2.4% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 2,295,319 | $37.7M | 2.6% | +2,295,319 | New | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,744,373 | $38.0M | 2.6% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 16,216,216 | $40.7M | 2.8% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,684,411 | $44.3M | 3.0% | +2440.0% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $51.2M | 3.5% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,249,731 | $52.9M | 3.6% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 3,220,130 | $61.7M | 4.2% | −175,476−5.2% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,685,448 | $62.5M | 4.3% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 3,285,620 | $63.7M | 4.4% | +200,000+6.5% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,709 | $74.4M | 5.1% | 00.0% | Unchanged | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 989,985 | $76.2M | 5.2% | +283,854+40.2% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,026,331 | $90.6M | 6.2% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 12,762,462 | $109.0M | 7.5% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $384.7M | 26.4% | 00.0% | Unchanged | History |
Sold out since Q3 2024 (4)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| EWTXEdgewise Therapeutics, Inc. | COM | 1,000,000 | $26.7M | 1.4% | History |
| ARVNArvinas, Inc. | COM | 454,450 | $11.2M | 0.6% | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,467,048 | $10.3M | 0.5% | History |
| CABACabaletta Bio, Inc. | COM | 1,563,952 | $7.38M | 0.4% | History |